参考文献/References:
[1] 朱静,徐健.心肌纤维化定量分析方法 [J]. 安徽医科大学学报,2012,47(11):1365-1368.
[2] 汪宇鹏,徐明,高炜.心肌纤维化相关生物标志物研究进展[J]. 生理科学进展,2010,41(6):461-463.
[3] 李彦明,何瑞利,钟晓鸣,等. 房颤患者血清CICP、PICP、BNP、AngⅡ水平与心功能的相关性[J]. 重庆医学,2019,48(4):688-690.
[4] Zhang G,Abuduoufu A,Zhou X,et al.Monocyte chemoattractant protein-1-induced protein in age-related atrial fibrillation and its association with circulating fibrosis biomarkers[J].Cardiology,2019,142(4):244-249.
[5] Jabati S,Fareed J,Liles J,et al.Biomarkers of inflammation,thrombogenesis,and collagen turnover in patients with atrial fibrillation[J].Clin Appl Thromb Hemost,2018,24(5):718-723.
[6] Sonmez O,Ertem FU,Vatankulu MA,et al. Novel fibro-inflammation markers in assessing left atrial remodeling in non-valvular atrial fibrillation[J]. Med Sci Monit,2014,20:463-470.
[7] Swartz MF, Fink GW, Sarwar MF, et a1.Elevated pre-operative serum peptides for collagenⅠand Ⅲ synthesis result in post-surgical atrial fibrillation[J]. J Am Coll Cardiol,2012,60(18):1799-1806.
[8] 李兴怡,刘佳,富路.心力衰竭合并室性心律失常的研究及治疗进展[J].心血管病学进展,2019,40(3):400-403.
[9] Nguyen MN,Kiriazis H,Ruggiero D,et al.Spontaneous ventricular tachyarrhythmias in β2-adrenoceptor transgenic mice in relation to cardiac interstitial fibrosis[J]. Am J Physiol Heart Circ Physiol,2015,309(5):H946-H957.
[10] Zhang B,Li X,Chen C,et al.Renal denervation effects on myocardial fibrosis and ventricular arrhythmias in rats with ischemic cardiomyopathy[J].Cell Physiol Biochem,2018,46(6):2471-2479.
[11] López B,Querejeta R,Gonzalez A,et al. Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure:potential role of lysyl oxidase [J]. Hypertension,2012,60(3):677-683.
[12] López B,González A,Querejeta R,et a1.Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin[J]. Eur J Heart Fail,2015,17(4):385-392.
[13] Bielecka-Dabrowa A,Michalska-Kasiczak M,Gluba A,et al. Biomarkers and echocardiographic predictors of myocardial dysfunction in patients with hypertension[J]. Sci Rep,2015,5:8916.
[14] Ambale Venkatesh B,Volpe GJ,Donekal S,et al. Association of longitudinal changes in left ventricular structure and function with myocardial fibrosis:the Multi-Ethnic Study of Atherosclerosis study[J]. Hypertension,2014,64(3):508-515.
[15] Bekar L,Katar M,Yetim M,et al.Fragmented QRS complexes are a marker of myocardial fibrosis in hypertensive heart disease[J]. Turk Kardiyol Dern Ars,2016,44(7):554-560.
[16] Chang YY,Wu YW,Lee JK,et al.Effects of 12weeks of atorvastatin therapy on myocardial fibrosis and circulating fibrosis biomarkers in statin-na?ve patients with hypertension with atherosclerosis[J]. J Investig Med,2016,64(7):1194-1199.
[17] Xie Y,Liao J,Yu Y,et a1.Endothelialtomesenchymal transition in human idiopathic dilated cardiomyopathy[J]. Mol Med Rep,2018,17(1):961-969.
[18] Rubi? P,Wi ?niowska-Smia?ek S,Wypasek E,et a1.12-month patterns of serum markers of collagen synthesis, transforming growth factor and connective tissue growth factor are similar in new-onset and chronic dilated cardiomyopathy in patients both with and without cardiac fibrosis[J]. Cytokine,2017,96:217-227.
[19] Nagao K,Inada T,Tamura A,et al.Circulating markers of collagen typesⅠ,Ⅲ, and Ⅳ in patients with dilated cardiomyopathy relationships with myocardial collagen expression[J]. ESC Heart Fail,2018,5(6):1044-1051.
[20] Ferreira JP,Duarte K,Montalescot G,et al. Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study[J]. Clin Res Cardiol,2018,107(1):49-59.
[21] Münch J,Avanesov M,Bannas P,et al.Serum matrix metalloproteinases as quantitative biomarkers for myocardial fibrosis and sudden cardiac death risk stratification in patients with hypertrophic cardiomyopathy[J]. J Card Fail,2016,22(10):845-850.
[22] Ferreira JP,Barros A,Pitt B,et al. Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial[J]. Clin Res Cardiol,2018,107(12):1192-1195.
[23] Lee CH,Lee WC,Chang SH,et al.The N-terminal propeptide of type Ⅲ procollagen in patients with acute coronary syndrome:a link between left ventricular end-diastolic pressure and cardiovascular events[J]. PLoS One,2015,10(1):e114097.
[24] Gao H,Zhang XS,Zhao Q,et al.Predictive value of serum collagen biomakers on the outcome of acute myocardial infarction treated with percutaneous coronary intervention[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2015,159(2):272-276.
[25] Lepoj?rvi ES,Piira OP,P??kk? E,et a l.Serum PⅠNP,PⅢNP,galectin-3,and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties[J]. Front Physiol,2015,6:200.
相似文献/References:
[1]郭君君,郑宏超,曹阳.生物标志物对急性心肌梗死介入治疗预后的预测意义[J].心血管病学进展,2016,(1):37.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.010]
GUO Junjun,ZHENG Hongchao,CAO Yang.Prognostic Significance of Biomarkers in Predicting Acute Myocardial
Infarction after Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2016,(5):37.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.010]
[2]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(5):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[3]耿春晖 关秀茹.MicroRNA作为动脉粥样硬化的诊断生物标志物的研究进展[J].心血管病学进展,2019,(7):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
GENG Chunhui,GUAN Xiuru.microRNA as a Diagnostic Biomarker for Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(5):996.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.008]
[4]晏露 李欣 柳志红.不同生物标志物在急性肺血栓栓塞症中的应用价值[J].心血管病学进展,2019,(5):687.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.007]
YAN Lu,LI Xin,LIU Zhihong.The unction of Different Biomarkers in Acute Pulmonary Embolism[J].Advances in Cardiovascular Diseases,2019,(5):687.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.007]
[5]韦余 胡科 温钞麟 邓玮.骨髓间充质干细胞干预心肌纤维化的增效措施[J].心血管病学进展,2019,(5):774.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.027]
Wei YuHu KeWen Chao LinDeng Wei.Synergistic Measures of Bone Marrow Mesenchymal Stem Cells in Intervention of Myocardial Fibrosis[J].Advances in Cardiovascular Diseases,2019,(5):774.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.027]
[6]孙敬辉 于永慧 王承龙.心肌纤维化研究的新领域——长链非编码RNA[J].心血管病学进展,2019,(9):1233.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.012]
SUN JinghuiYU YonghuiWANG Chenglong.Long No-Coding RNAA New Field of Myocardial Fibrosis[J].Advances in Cardiovascular Diseases,2019,(5):1233.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.012]
[7]刘壮壮 黄宇理.心力衰竭生物标志物的研究进展[J].心血管病学进展,2020,(1):67.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.018]
LIU Zhuangzhuang,HUANG Yuli.Biomarkers for Heart Failure[J].Advances in Cardiovascular Diseases,2020,(5):67.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.018]
[8]位晨晨,钟明.糖尿病心肌病的发病机制[J].心血管病学进展,2020,(2):135.[doi:10.16806/j.cnki.issn.1004-3934.20.02.009]
WEI Chenchen,ZHONG Ming.Pathogenesis of Diabetic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(5):135.[doi:10.16806/j.cnki.issn.1004-3934.20.02.009]
[9]刘玉婷,贾锋鹏.骨膜蛋白与心血管疾病的研究进展[J].心血管病学进展,2020,(3):239.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.006]
LIU Yuting,JIA Fengpeng.Roles of Periostin in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(5):239.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.006]
[10]王同霞 陈章荣.可溶ST2与心力衰竭患者预后的评价[J].心血管病学进展,2020,(5):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]
WANG Tongxia,CHEN Zhangrong.Prognosis of Heart Failure Patients and Soluble ST2[J].Advances in Cardiovascular Diseases,2020,(5):495.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.013]